ArticlePloS one2025
User informed design of oral dispersible strips (ODS) to deliver pediatric antiretroviral therapy in Kenya: A mixed methods evaluation of product preferences and acceptability.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInnovation to streamline the administration of pediatric antiretroviral therapy to infants and small children is urgently needed. The objective of this study was to assess user acceptability of key characteristics of prototype placebo oral dispersible strips (ODS) that would contain a pediatric HIV regimen of abacavir + lamivudine+ dolutegravir (ALD), and the extent to which they would address current barriers to ART adherence.
methodsWe conducted 7 focus group discussions with 64 caregivers across three hospitals; 3 FGD with 25 pediatric healthcare providers; and interviews with 25 children living with HIV (6-10 years). All FGD and interviews were audio recorded, translated, transcribed verbatim, and coded for a-priori and emergent themes. We evaluated the acceptability of key characteristics of placebo ALD-ODS (e.g.,flavor, size, dose, dissolution time, colors, and packaging) among caregivers, providers, and children using both qualitative and quantitative methods. Data were integrated and triangulated to optimize understanding of stakeholder feedback.
resultsAdult participants preferred the neutral "sweet" flavored ALD-ODS which was found highly acceptable among children. Caregivers advocated for a single strip per dose and single dose per day for convenience and to reduce stress of administration. In general, strip size and dissolution time was deemed acceptable, and caregivers stated that a larger size would be acceptable to accommodate a single strip per dose. Providers liked aligning the color of ALD-ODS and its packaging to different weight-based dosing to facilitate dispensing and improve accurate administration among multiple children. Most children stated that they would prefer ALD-ODS to their current regimen given the sweet taste and easy dissolution without the need for water. The competitive advantages of ALD-ODS over traditional pediatric ART options were ease of administration- particularly for infants and small children, a sweet taste, and discretion that protected privacy.
conclusionProviders and caregivers believed the ODS prototypes held great promise to ease ART administration to infants and young children which would improve medication adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.